PortalPublikationenLong-term efficacy and safety of asenapine or olanzapine in ...

Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.

Standard

Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. / Schoemaker, J; Stet, L; Vrijland, P; Naber, Dieter; Panagides, J; Emsley, R.

in: PHARMACOPSYCHIATRY, Jahrgang 45, Nr. 5, 5, 2012, S. 196-203.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schoemaker, J, Stet, L, Vrijland, P, Naber, D, Panagides, J & Emsley, R 2012, 'Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.', PHARMACOPSYCHIATRY, Jg. 45, Nr. 5, 5, S. 196-203. <http://www.ncbi.nlm.nih.gov/pubmed/22454251?dopt=Citation>

APA

Schoemaker, J., Stet, L., Vrijland, P., Naber, D., Panagides, J., & Emsley, R. (2012). Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. PHARMACOPSYCHIATRY, 45(5), 196-203. [5]. http://www.ncbi.nlm.nih.gov/pubmed/22454251?dopt=Citation

Vancouver

Schoemaker J, Stet L, Vrijland P, Naber D, Panagides J, Emsley R. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. PHARMACOPSYCHIATRY. 2012;45(5):196-203. 5.

Bibtex

@article{e489311764bf4181948219222ab01daa,
title = "Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.",
abstract = "Safety and efficacy results, collected in schizophrenia and schizoaffective disorder patients treated for up to nearly 3 years, are presented for asenapine and olanzapine.",
keywords = "Adult, Humans, Male, Female, Middle Aged, Psychiatric Status Rating Scales, Treatment Outcome, Longitudinal Studies, Dose-Response Relationship, Drug, Diagnostic and Statistical Manual of Mental Disorders, Time, Drug Monitoring, Pharmacovigilance, Comparative Effectiveness Research, Antipsychotic Agents/administration & dosage/adverse effects, Basal Ganglia Diseases/*chemically induced, *Benzodiazepines/administration & dosage/adverse effects, *Heterocyclic Compounds with 4 or More Rings/administration & dosage/adverse effects, Psychotic Disorders/diagnosis/*drug therapy, Schizophrenia/diagnosis/*drug therapy, Weight Gain/*drug effects, Adult, Humans, Male, Female, Middle Aged, Psychiatric Status Rating Scales, Treatment Outcome, Longitudinal Studies, Dose-Response Relationship, Drug, Diagnostic and Statistical Manual of Mental Disorders, Time, Drug Monitoring, Pharmacovigilance, Comparative Effectiveness Research, Antipsychotic Agents/administration & dosage/adverse effects, Basal Ganglia Diseases/*chemically induced, *Benzodiazepines/administration & dosage/adverse effects, *Heterocyclic Compounds with 4 or More Rings/administration & dosage/adverse effects, Psychotic Disorders/diagnosis/*drug therapy, Schizophrenia/diagnosis/*drug therapy, Weight Gain/*drug effects",
author = "J Schoemaker and L Stet and P Vrijland and Dieter Naber and J Panagides and R Emsley",
year = "2012",
language = "English",
volume = "45",
pages = "196--203",
journal = "PHARMACOPSYCHIATRY",
issn = "0176-3679",
publisher = "Georg Thieme Verlag KG",
number = "5",

}

RIS

TY - JOUR

T1 - Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.

AU - Schoemaker, J

AU - Stet, L

AU - Vrijland, P

AU - Naber, Dieter

AU - Panagides, J

AU - Emsley, R

PY - 2012

Y1 - 2012

N2 - Safety and efficacy results, collected in schizophrenia and schizoaffective disorder patients treated for up to nearly 3 years, are presented for asenapine and olanzapine.

AB - Safety and efficacy results, collected in schizophrenia and schizoaffective disorder patients treated for up to nearly 3 years, are presented for asenapine and olanzapine.

KW - Adult

KW - Humans

KW - Male

KW - Female

KW - Middle Aged

KW - Psychiatric Status Rating Scales

KW - Treatment Outcome

KW - Longitudinal Studies

KW - Dose-Response Relationship, Drug

KW - Diagnostic and Statistical Manual of Mental Disorders

KW - Time

KW - Drug Monitoring

KW - Pharmacovigilance

KW - Comparative Effectiveness Research

KW - Antipsychotic Agents/administration & dosage/adverse effects

KW - Basal Ganglia Diseases/chemically induced

KW - Benzodiazepines/administration & dosage/adverse effects

KW - Heterocyclic Compounds with 4 or More Rings/administration & dosage/adverse effects

KW - Psychotic Disorders/diagnosis/drug therapy

KW - Schizophrenia/diagnosis/drug therapy

KW - Weight Gain/drug effects

KW - Adult

KW - Humans

KW - Male

KW - Female

KW - Middle Aged

KW - Psychiatric Status Rating Scales

KW - Treatment Outcome

KW - Longitudinal Studies

KW - Dose-Response Relationship, Drug

KW - Diagnostic and Statistical Manual of Mental Disorders

KW - Time

KW - Drug Monitoring

KW - Pharmacovigilance

KW - Comparative Effectiveness Research

KW - Antipsychotic Agents/administration & dosage/adverse effects

KW - Basal Ganglia Diseases/chemically induced

KW - Benzodiazepines/administration & dosage/adverse effects

KW - Heterocyclic Compounds with 4 or More Rings/administration & dosage/adverse effects

KW - Psychotic Disorders/diagnosis/drug therapy

KW - Schizophrenia/diagnosis/drug therapy

KW - Weight Gain/drug effects

M3 - SCORING: Journal article

VL - 45

SP - 196

EP - 203

JO - PHARMACOPSYCHIATRY

JF - PHARMACOPSYCHIATRY

SN - 0176-3679

IS - 5

M1 - 5

ER -